Our integrated findings establish a feedforward resistance loop: Gefitinib treatment paradoxically enhances tumor cell CCL2 secretion, driving TAMs infiltration that subsequently secretes protective factors to diminish drug efficacy. The gene discussed is CCL2; the disease is neoplasm.